ProCE Banner Activity

Frequently Asked Questions in HER2-Positive Metastatic Breast Cancer Care

Clinical Thought
Read expert answers to audience questions from a CCO Webinar on current best practices and emerging options for patients with HER2-positive MBC.

Released: September 11, 2020

Expiration: September 10, 2021

Share

Faculty

Cristina Saura

Cristina Saura, MD, PhD

Medical Oncologist
Vall d’Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Cristina Saura, MD, PhD

Medical Oncologist
Vall d’Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Cristina Saura, MD, PhD, has disclosed that she has received consulting fees or travel grants from AstraZeneca, Celgene, Daiichi Sankyo, Eisai, F. Hoffmann-La Roche, Genomic Health, Merck, Novartis, Pfizer, Philips HealthWorks, Pierre Fabre, Puma, Sanofi, Seattle Genetics, and Synthon.